PMID- 12559628
OWN - NLM
STAT- MEDLINE
DCOM- 20030926
LR  - 20201222
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 64
IP  - 2
DP  - 2003 Feb
TI  - Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific 
      to nonclassical HLA-G antigen with classical HLA class I molecules.
PG  - 256-64
AB  - Mild acid treatment by releasing beta(2)m and antigenic peptides leaves human 
      leukocyte antigen (HLA) class I free heavy chains attached to the cell surface. 
      Acid treatment thus allows detection of the cell surface class I antigens by 
      monoclonal antibodies (mAbs) specific to HLA-free heavy chains. We found that 
      acid treatment also enables detection of the cell surface non-classical HLA-G 
      class I antigen with mAbs specific for HLA-G free heavy chains, including 4H84 
      mAb recognizing all isoforms. Furthermore, we found that 4H84 mAb, but not other 
      mAbs specific to HLA-G free heavy chains, binds to the surface of 8 out of 16 
      acid-treated leukemia cell lines. Nevertheless, HLA-G antigen is not present in 
      any of these leukemia cells. This was demonstrated by failure to detect any 
      antigen with 4H84 mAb in immunoblotting as well as by inability to detect HLA-G 
      mRNA by RT-PCR. The antigen recognized by 4H84 mAb in some acid treated leukemia 
      cells was identified by immunoprecipitation as a 45 kDa protein. A number of 
      observations indicate that 45 kDa proteins are none other than classical class I 
      heavy chains. Acid treatment thus induces the ability of the 4H84 mAb to 
      recognize some classical HLA class I molecules. Remarkably, 4H84 determinant on 
      HLA-G is linear but corresponding determinant present on some partially folded 
      classical HLA class I free heavy chains is conformational. In view of the 
      unexpected cross-reactivity, detection of HLA-G with this mAb must be carefully 
      evaluated to avoid false detection.
FAU - Polakova, Katarina
AU  - Polakova K
AD  - Cancer Research Institute, Bratislava, Slovak Republic.
FAU - Bennink, Jack R
AU  - Bennink JR
FAU - Yewdell, Jonathan W
AU  - Yewdell JW
FAU - Bystricka, Magdalena
AU  - Bystricka M
FAU - Bandzuchova, Elena
AU  - Bandzuchova E
FAU - Russ, Gustav
AU  - Russ G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Phosphates)
RN  - 0 (Protein Isoforms)
RN  - 0 (beta 2-Microglobulin)
RN  - 2968PHW8QP (Citric Acid)
RN  - SE337SVY37 (sodium phosphate)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology
MH  - Antibody Specificity
MH  - Antigens, Neoplasm/immunology
MH  - Antigens, Surface/immunology
MH  - Choriocarcinoma/pathology
MH  - Citric Acid/*pharmacology
MH  - Cross Reactions
MH  - Epitopes/immunology
MH  - Female
MH  - HLA Antigens/drug effects/*immunology
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/drug effects/*immunology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Immunoblotting
MH  - Leukemia/pathology
MH  - Phosphates/pharmacology
MH  - Protein Denaturation
MH  - Protein Isoforms/immunology
MH  - Tumor Cells, Cultured/drug effects/immunology
MH  - Uterine Neoplasms/pathology
MH  - beta 2-Microglobulin/immunology
EDAT- 2003/02/01 04:00
MHDA- 2003/09/27 05:00
CRDT- 2003/02/01 04:00
PHST- 2003/02/01 04:00 [pubmed]
PHST- 2003/09/27 05:00 [medline]
PHST- 2003/02/01 04:00 [entrez]
AID - S0198885902007772 [pii]
AID - 10.1016/s0198-8859(02)00777-2 [doi]
PST - ppublish
SO  - Hum Immunol. 2003 Feb;64(2):256-64. doi: 10.1016/s0198-8859(02)00777-2.